GlassScriptPhysician profile
Kenneth B Gossler
NPI 1942292628
$9,643.65
in general payments reported to CMS, 2019-2025
29 companies · $29.19 in 2025
The $29.19 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,565 · 2020: $1,056 · 2021: $1,794 · 2022: $2,901 · 2023: $1,130 · 2024: $169 · 2025: $29.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,021.43 | 2019-2025 | Proclaim, Eterna, Octrode |
| Vertos Medical, INC. | $616.85 | 2022-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $565.26 | 2019-2023 | Xtampza, Belbuca |
| Nevro Corp. | $398.75 | 2019-2023 | Senza |
| Pacira Therapeutics, INC. | $286.07 | 2019-2021 | |
| Boston Scientific Corporation | $233.72 | 2021-2022 | |
| Zyla Life Sciences, INC. | $173.17 | 2019 | |
| Biodelivery Sciences International, INC. | $123.32 | 2019-2021 | |
| Relievant Medsystems, INC. | $120.34 | 2020 | |
| Nalu Medical, INC. | $116.08 | 2021-2023 | Nalu Neurostimulation System |
| Novartis Pharmaceuticals Corporation | $108.47 | 2019 | |
| Amgen INC. | $104.79 | 2019-2021 | |
| Painteq LLC | $91.73 | 2022 | |
| Ferring Pharmaceuticals INC. | $91.31 | 2020-2022 | |
| Spr Therapeutics, INC | $81.09 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $62.61 | 2023 | Qutenza |
| Grt US Holding, INC. | $62.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.49 | 2022-2023 | Relistor |
| Saluda Medical Americas, INC. | $55.53 | 2023 | Evoke Scs |
| Acacia Pharma INC | $47.06 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $43.78 | 2019-2021 | |
| Lilly USA, LLC | $40.35 | 2019-2020 | |
| Depuy Synthes Sales INC. | $37.06 | 2022 | |
| Orthogenrx INC. | $29.94 | 2019 | |
| Curonix LLC | $20.54 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mdd US Operations, LLC | $16.74 | 2019 | |
| Horizon Therapeutics Plc | $13.36 | 2019 | |
| Medtronic, INC. | $12.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Gossler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.